TWST
Twist Bioscience Corp

4,071
Mkt Cap
$2.06B
Volume
9,057.00
52W High
$55.33
52W Low
$24.07
PE Ratio
-23.49
TWST Fundamentals
Price
$34.11
Prev Close
$31.83
Open
$32.84
50D MA
$28.45
Beta
2.28
Avg. Volume
1.63M
EPS (Annual)
-$3.60
P/B
4.29
Rev/Employee
$339,083.42
Loading...
Loading...
News
all
press releases
Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders...
Business Wire·3d ago
News Placeholder
More News
News Placeholder
Twist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year...
Business Wire·4d ago
News Placeholder
Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm
Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm PR Newswire NEW YORK, Oct. 16...
PR Newswire·11d ago
News Placeholder
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth; Halozyme, Akero, Kiniska, ANI and Twist stand out.
Zacks·1mo ago
News Placeholder
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector
Zacks·1mo ago
News Placeholder
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Zacks·1mo ago
News Placeholder
After Plunging 33.8% in 4 Weeks, Here's Why the Trend Might Reverse for Twist Bioscience (TWST)
The heavy selling pressure might have exhausted for Twist Bioscience (TWST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·3mo ago
News Placeholder
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of +12.96% and +0.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Twist Bioscience to Present at Upcoming Investor Conferences
Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that its executives will...
Business Wire·8mo ago
News Placeholder
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (Twist or the Company), a core mid-cap growth and value equity company in the life sciences segment of...
Business Wire·8mo ago

Latest TWST News

View

Advertisement|Remove ads.

Advertisement|Remove ads.